Sanjiv Patel - 31 Dec 2021 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President and CEO, Director
Signature
/s/ Brian Adams, as Attorney-in-Fact
Issuer symbol
RLAY
Transactions as of
31 Dec 2021
Net transactions value
+$17,174
Form type
4
Filing time
07 Jan 2022, 16:13:41 UTC
Previous filing
12 Jul 2021
Next filing
31 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $17,174 +658 +0.26% $26.10 253,740 31 Dec 2021 Direct F1, F2
holding RLAY Common Stock 674,548 31 Dec 2021 By The Patel Family Irrevocable Trust of 2019 F3
holding RLAY Common Stock 432,801 31 Dec 2021 By The SSP Irrevocable Trust of 2020 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 31, 2021.
F3 These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.